Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Liver Cancer

10 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Diagnostic

    VICCGI14124

    03/13/2015

    PET Imaging of Hepatocellular Carcinoma with 18F-FSPG

    Other

    VICCGI1523

    07/01/2015

    Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Study

    Prevention

    VICCPED1698

    06/23/2017

    A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant

    Treatment

    VICCGI1754

    11/22/2017

    A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

    Treatment

    VICCGI16149

    11/10/2017

    An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

    Treatment

    VICCMD15107

    11/07/2017

    A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

    Treatment

    VICCMD15133

    10/06/2016

    A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma not Amenable to Resection or Transplant

    Treatment

    VICCMD15110

    04/05/2016

    A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

    Treatment

    CTSUGI80702-M

    05/05/2011

    A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or placebo for patients with Resected Stage III Colon Cancer

    Treatment

    CTSUGIC80802-M

    12/07/2010

    Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)


    Print this page for your doctor